Eisai U.s. Neurology

Eisai U.S. Neurology is a division of Eisai Inc., the American subsidiary of the global Japanese pharmaceutical company Eisai Co., Ltd., focused on developing and commercializing innovative therapies for neurological disorders such as Alzheimer's disease and epilepsy. The company generates revenue primarily through the research, development, and sale of prescription medications, including notable products like Leqembi (lecanemab) for Alzheimer's and Fycompa for epilepsy. Eisai has a longstanding commitment to human health care (hhc), emphasizing patient-centric approaches and strategic collaborations, including partnerships with Biogen and other biotech firms. Candidates should be aware of Eisai's significant role in advancing neurology treatments, its robust clinical pipeline, and its reputation for ethical research and global impact. The company values scientific innovation, collaboration, and a mission-driven culture aimed at addressing unmet medical needs in neurology.

Recent Posts by Eisai U.s. Neurology

1-20 of 178